Similar articles

• Commentary: The debate on non-inferiority trials: 'when meta-analysis alone is not helpful'.

  Liberati A, D'Amico R. Liberati A, et al. Int J Epidemiol. 2010 Dec;39(6):1582-3. doi: 10.1093/ije/dyq197. Int J Epidemiol. 2010. PMID: 21113051 No abstract available.
• Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses.

  Hart B, Lundh A, Bero L. Hart B, et al. BMJ. 2012 Jan 3;344:d7202. doi: 10.1136/bmj.d7202. BMJ. 2012. PMID: 22214754
• Bias resulting from the use of 'assay sensitivity' as an inclusion criterion for meta-analysis.

  Gelfand LA, Strunk DR, Tu XM, Noble RE, Derubeis RJ. Gelfand LA, et al. Stat Med. 2006 Mar 30;25(6):943-55. doi: 10.1002/sim.2240. Stat Med. 2006. PMID: 16196080
• Most meta-analyses of drug interventions have narrow scopes and many focus on specific agents.

  Haidich AB, Pilalas D, Contopoulos-Ioannidis DG, Ioannidis JP. Haidich AB, et al. J Clin Epidemiol. 2013 Apr;66(4):371-8. doi: 10.1016/j.jclinepi.2012.10.014. Epub 2013 Feb 4. J Clin Epidemiol. 2013. PMID: 23384590 Review.
• Improvement of phase III psychotropic drug trials by intensive phase II work.

  Klein DF. Klein DF. Neuropsychopharmacology. 1991 Jun;4(4):251-8; discussion 259-71. Neuropsychopharmacology. 1991. PMID: 1867735 Review.